BR9913515A - Análogo de grf hidrófobo, formulação farmacêutica, uso de análogo de grf, e, processo para o diagnóstico de deficiências de hormÈnio de crescimento em pacientes - Google Patents

Análogo de grf hidrófobo, formulação farmacêutica, uso de análogo de grf, e, processo para o diagnóstico de deficiências de hormÈnio de crescimento em pacientes

Info

Publication number
BR9913515A
BR9913515A BR9913515-9A BR9913515A BR9913515A BR 9913515 A BR9913515 A BR 9913515A BR 9913515 A BR9913515 A BR 9913515A BR 9913515 A BR9913515 A BR 9913515A
Authority
BR
Brazil
Prior art keywords
graph
analog
hydrophobic
diagnosis
growth hormone
Prior art date
Application number
BR9913515-9A
Other languages
English (en)
Inventor
Denis Gravel
Abdelkrim Habi
Paul Brazeau
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/148,982 external-priority patent/US6020311A/en
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of BR9913515A publication Critical patent/BR9913515A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"ANáLOGO DE GRF HIDRóFOBO, FORMULAçãO FARMACêUTICA, USO DE ANáLOGO DE GRF, E, PROCESSO PARA O DIAGNóSTICO DE DEFICIêNCIAS DE HORMÈNIO DE CRESCIMENTO EM PACIENTES". A presente invenção refere-se a análogos de GRF- corpo graxo quimérico com aumentada potência biológica, sua aplicação como agentes anabólicos e no diagnóstico e tratamento de deficiências de hormónio de crescimento. Os análogos de GRF- corpo graxo quimérico incluem uma porção hidrófoba (cauda) e podem ser preparados, por ancoragem de pelo menos uma cauda hidrófoba ao GRF, na síntese química de GRF. Os análogos de GRF da presente invenção são biodegradáveis, não imunogênicos e demonstram uma melhorada potência anabólica com uma reduzida dosagem e prolongada atividade.
BR9913515-9A 1998-09-08 1999-09-07 Análogo de grf hidrófobo, formulação farmacêutica, uso de análogo de grf, e, processo para o diagnóstico de deficiências de hormÈnio de crescimento em pacientes BR9913515A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/148,982 US6020311A (en) 1995-05-26 1998-09-08 GRF analogs with increased biological potency
US09/389,486 US6458764B1 (en) 1995-05-26 1999-09-03 GRF analogs with increased biological potency
PCT/CA1999/000816 WO2000014236A2 (en) 1998-09-08 1999-09-07 Grf analogs with increased biological potency

Publications (1)

Publication Number Publication Date
BR9913515A true BR9913515A (pt) 2001-06-05

Family

ID=26846360

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913515-9A BR9913515A (pt) 1998-09-08 1999-09-07 Análogo de grf hidrófobo, formulação farmacêutica, uso de análogo de grf, e, processo para o diagnóstico de deficiências de hormÈnio de crescimento em pacientes

Country Status (12)

Country Link
US (2) US6458764B1 (pt)
EP (1) EP1109909B1 (pt)
JP (1) JP2002524472A (pt)
KR (1) KR100474868B1 (pt)
AT (1) ATE311453T1 (pt)
AU (1) AU755852B2 (pt)
BR (1) BR9913515A (pt)
CA (1) CA2342070A1 (pt)
DE (2) DE1109909T1 (pt)
ES (1) ES2164626T1 (pt)
MX (1) MXPA01002468A (pt)
WO (1) WO2000014236A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
BR0113178A (pt) * 2000-08-02 2004-04-06 Theratechnologies Inc Peptìdeos biológicos modificados com potência aumentada
JP2006504694A (ja) * 2002-09-18 2006-02-09 サントル・オスピタリエ・ドゥ・リュニヴェルシテ・ドゥ・モントリオール・（シー・エイチ・ユー・エム） Ｇｈｒｈ類似体
MXPA05004202A (es) * 2002-10-22 2005-09-20 Waratah Pharmaceuticals Inc Tratamiento de la diabetes.
EP2382984A3 (en) * 2003-05-29 2011-11-23 Theratechnologies Inc. GRF analog compositions and their use
JP5030590B2 (ja) * 2003-09-02 2012-09-19 イスム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム バクテリアエフェクターとしてのオキサザボロリディン類
EP1675610A4 (en) * 2003-10-20 2010-04-28 Theratechnologies Inc USE OF GROWTH HORMONE RELEASE FACTOR ANALOGUE IN THE TREATMENT OF PATIENTS WITH EXCEPTION
JP2008516994A (ja) * 2004-10-20 2008-05-22 セラテクノロジーズ、インコーポレイテッド 成長ホルモン分泌促進因子およびその使用
PT1869066E (pt) * 2005-04-08 2010-02-03 Lonza Ag Síntese de peptídeo de hélice-alfa sobre resina peg
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
WO2011153491A2 (en) 2010-06-03 2011-12-08 University Of Miami Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
WO2013059525A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
US9079974B2 (en) 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
CN108912211A (zh) 2012-02-15 2018-11-30 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
SG11201404648PA (en) 2012-02-15 2014-09-26 Aileron Therapeutics Inc Peptidomimetic macrocycles
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
EP2934565B1 (en) 2012-12-21 2019-03-13 University of Miami Ghrh agonists for the treatment of ischemic disorders
EP2935317B1 (en) 2012-12-21 2019-03-27 University of Miami Ghrh agonists for islet cell transplantation and function and the treatment of diabetes
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2023014978A2 (en) * 2021-08-06 2023-02-09 Rebalance Health, Inc. Growth hormone-releasing hormone peptides and formulations thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914189A (en) * 1987-02-05 1990-04-03 The Adminstrators Of The Tulane Educational Fund Synthetic GHRH analogs
US5112808A (en) * 1987-05-11 1992-05-12 American Cyanamid Company Alkylated hormone-releasing peptides and method of treatig mammals therewith
EP0527914A4 (en) * 1990-05-04 1993-08-11 The Administrators Of The Tulane University Educational Fund Novel synthetic grf analogs
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
AU697119B2 (en) * 1995-05-26 1998-09-24 Theratechnologies Inc. Chimeric fatty body-pro-GRF analogs with increased biological potency
US6020311A (en) * 1995-05-26 2000-02-01 Theratechnologies, Inc. GRF analogs with increased biological potency

Also Published As

Publication number Publication date
CA2342070A1 (en) 2000-03-16
DE69928677D1 (de) 2006-01-05
KR20010086368A (ko) 2001-09-10
ES2164626T1 (es) 2002-03-01
WO2000014236A2 (en) 2000-03-16
JP2002524472A (ja) 2002-08-06
EP1109909B1 (en) 2005-11-30
KR100474868B1 (ko) 2005-03-08
EP1109909A2 (en) 2001-06-27
AU5500799A (en) 2000-03-27
ATE311453T1 (de) 2005-12-15
DE1109909T1 (de) 2002-05-23
WO2000014236A3 (en) 2000-06-02
US6458764B1 (en) 2002-10-01
MXPA01002468A (es) 2002-04-24
AU755852B2 (en) 2002-12-19
US20040171534A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
BR9913515A (pt) Análogo de grf hidrófobo, formulação farmacêutica, uso de análogo de grf, e, processo para o diagnóstico de deficiências de hormÈnio de crescimento em pacientes
BRPI9608799B8 (pt) análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.
ES2187575T3 (es) Hexapeptidos ciclicos dotados de actividad antibiotica.
ATE494902T1 (de) Ein huhn gnrh-ii analog zur verwendung in der reduktion des tumorzellwachstums
AR007715A1 (es) Formulacion acuosa estable de un peptido, un metodo para preparar la misma y su uso para tratamiento
NL193308B (nl) Doseervorm geschikt voor de afgifte van een preparaat van een heilzaam middel aan een gebruiksomgeving.
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
NO842291L (no) Fremgangsmaate for fremstilling av orale antidiabetiske substanser.
DE69434418D1 (de) Orale Dareichungsform
DE60000288T2 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
DE59902270D1 (de) Feuchtigkeitsaktivierbares therapeutisches system
GR3005612T3 (pt)
BR0304298A (pt) Composição contendo um ácido orgânico cosmeticamente ativo e um produto de legume
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
BR9106676A (pt) Peptideo,processo para promover a liberacao de niveis de hormonio de crescimento em um animal,composicao farmaceutica para promover a liberacao de niveis de hormonio de crescimento em animais,uso do composto e processo para promover a liberacao e elevacao de niveis de hormonio de crescimento no sangue
BR9911756A (pt) Composto, uso de um secretagogo do hormÈnio do crescimento ou um seu sal farmaceuticamente aceitável, composição farmacêutica, método para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero, e, uso de um composto
DE69736985D1 (de) Biologisch aktive zusammensetzung
BR9906975A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
CO4930262A1 (es) Producto farmaceutico cristalino, su preparacion y uso como sustancia terapeutica
AR014969A1 (es) Formulacion que contienen por lo menos una proteina tardia (proteina l) de uno o mas papilomavirus y/o por lo menos una proteina temprana (proteina e) deuno o mas papilomavirus, procedimiento para la preparacion de la formulacion mencionada asi como su utilizacion para la manufactura de un medicamen
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
ECSP003659A (es) Metodo para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes
EP1935885A3 (en) Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues.
IT1233426B (it) Composizioni farmaceutiche per uso orale ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo, e procedimento per prepararle

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A E 10A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2012 DE 28/07/2009.